In order to provide additional evidence that the effects seen were due to down-regulation of p96ABL/BCR and not to that of endogenous BCR, we utilized a TEL/ABL-expressing PD-LTC (VG) derived from a patient with t(12;9)(p13;q34)-positive ALL, previously described [24]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.